Oct. 25 at 9:54 AM
$GNPX Setup looks smarter than people think 🔥
The reverse split and small offering before the AACR presentation were actually well timed. They cleared compliance without tanking the stock. Just enough to reset and give the company room to move.
Now all eyes are on today’s data at AACR-NCI-EORTC (Poster Session C) — focused on TUSC2 (REQORSA) in ALK-positive cancers.
If the results hit, it’s not just validation… it’s expansion. That’s new market potential and a major credibility boost.
Feels like they’ve positioned this perfectly, cleaned up the balance, tightened the float, and now bringing the science front and centre.
Could be the start of a real turnaround.
#GNPX #REQORSA #GeneTherapy #AACR2025
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/program-saturday-october-25/